Latest Sirolimus Stories

2012-05-02 15:07:00

IDIBELL researchers discover that combining two mTOR inhibitors cause the regression of hepatocellular carcinoma The combination of two inhibitors of protein mTOR stops the growth of primary liver cancer and destroys tumor cells, according to a study by researchers of the Group of Metabolism and Cancer at Bellvitge Biomedical Research Institute (IDIBELL). The study results are been published on the online edition of the journal Science Translational Medicine. Primary liver cancer or...

2012-05-01 21:18:47

Scientists at Joslin Diabetes Center have identified a key mechanism of action for the TOR (target of rapamycin) protein kinase, a critical regulator of cell growth which plays a major role in illness and aging. This finding not only illuminates the physiology of aging but could lead to new treatments to increase lifespan and control age-related conditions, such as cancer, type 2 diabetes, and neurodegeneration. Over the past decade, studies have shown that inhibiting TOR activity, which...

Study Reveals Why Rapamycin Causes Diabetes-like Symptoms
2012-04-04 11:01:49

Rapamycin is an immunosuppressant derived from bacteria found on Easter Island. It was approved for organ transplant patients by the FDA in 1999. The drug helps to prevent organ rejection and is currently undergoing clinical trials as a cancer treatment. It shows promise for its anti-cancer activity and may even slow the aging process. Pere Puigserver of Dana-Farber Cancer Institute says, “This is a drug that is pretty well known for its benefits. Rapamycin is one of the few drugs,...

2012-04-02 15:53:36

Aberrations in translation regulators associated with hormone receptor-positive disease survival Four proteins involved in translation, the final step of general protein production, are associated with poor prognosis in hormone-receptor-positive breast cancer when they are dysregulated, researchers reported at the AACR Annual Meeting 2012. All of the aberrantly activated translational proteins are regulated by the PI3K/mTOR molecular signaling pathway, which has been implicated in...

2012-04-02 09:09:21

Researchers control drug side effects for treatment gains in Phase I trial A pair of targeted therapies shrank tumors in some patients with treatment-resistant Ewing's sarcoma or desmoplastic small-round-cell tumors, according to research led by investigators from The University of Texas MD Anderson Cancer Center reported at the AACR Annual Meeting 2012. Five of 17 Ewing's sarcoma patients responded to the combination, with two achieving complete responses, one for 27 weeks. The...

2012-03-29 23:31:50

FINDINGS: The drug rapamycin has been shown to extend lifespan in lab animals, yet rapamycin has also been linked to impaired glucose tolerance and insulin sensitivity, two hallmarks of diabetes. By teasing apart rapamycin's activity at the cellular level, researchers at Whitehead Institute and the University of Pennsylvania have determined that inhibiting only the protein cluster known as the mechanistic target of rapamycin complex 1 (mTORC1) prolongs life in mice without adversely affecting...

2012-03-29 23:30:40

Rapamycin-induced longevity in mice can be uncoupled from diabetes-inducing side effects A Penn- and MIT-led team explained how rapamycin, a drug that extends mouse lifespan, also causes insulin resistance. The researchers showed in an animal model that they could, in principle, separate the effects, which depend on inhibiting two protein complexes, mTORC1 and mTORC2, respectively. The study suggests that molecules that specifically inhibit mTORC1 may combat age-related diseases without...

Word of the Day
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'